- Home
- AVDL vs PHAR Comparison
AVDL vs PHAR Comparison
Compare AVDL & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDL
- PHAR
- Stock Information
- Founded
- AVDL 2015
- PHAR 1988
- Country
- AVDL Ireland
- PHAR Netherlands
- Employees
- AVDL N/A
- PHAR N/A
- Industry
- AVDL Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- AVDL Health Care
- PHAR Health Care
- Exchange
- AVDL Nasdaq
- PHAR Nasdaq
- Market Cap
- AVDL 786.3M
- PHAR 679.0M
- IPO Year
- AVDL 1996
- PHAR N/A
- Fundamental
- Price
- AVDL $7.64
- PHAR $8.94
- Analyst Decision
- AVDL Strong Buy
- PHAR Strong Buy
- Analyst Count
- AVDL 6
- PHAR 3
- Target Price
- AVDL $20.00
- PHAR $27.00
- AVG Volume (30 Days)
- AVDL 1.7M
- PHAR 5.8K
- Earning Date
- AVDL 03-03-2025
- PHAR 03-13-2025
- Dividend Yield
- AVDL N/A
- PHAR N/A
- EPS Growth
- AVDL N/A
- PHAR N/A
- EPS
- AVDL N/A
- PHAR N/A
- Revenue
- AVDL $138,160,000.00
- PHAR $285,745,000.00
- Revenue This Year
- AVDL $515.63
- PHAR $20.08
- Revenue Next Year
- AVDL $49.32
- PHAR $9.22
- P/E Ratio
- AVDL N/A
- PHAR N/A
- Revenue Growth
- AVDL 1523.50
- PHAR 30.64
- 52 Week Low
- AVDL $7.39
- PHAR $6.65
- 52 Week High
- AVDL $19.09
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- AVDL 30.42
- PHAR 44.71
- Support Level
- AVDL $7.40
- PHAR $8.81
- Resistance Level
- AVDL $8.01
- PHAR $10.01
- Average True Range (ATR)
- AVDL 0.44
- PHAR 0.56
- MACD
- AVDL -0.07
- PHAR -0.15
- Stochastic Oscillator
- AVDL 6.93
- PHAR 9.90
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.